Device Management in Heart Failure

go back to reference Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2004;110:2180–3.CrossRefPubMed Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2004;110:2180–3.CrossRefPubMed

go back to reference Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail. 1999;1:41–5.CrossRefPubMed Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail. 1999;1:41–5.CrossRefPubMed

go back to reference Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-digoxin study group. J Am Coll Cardiol. 1989;14:564–70.CrossRefPubMed Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-digoxin study group. J Am Coll Cardiol. 1989;14:564–70.CrossRefPubMed

go back to reference Szabó BM, van Veldhuisen DJ, Crijns HJ, et al. Value of ambulatory electrocardiographic monitoring to identify increased risk of sudden death in patients with left ventricular dysfunction and heart failure. Eur Heart J. 1994;15:928–33.CrossRefPubMed Szabó BM, van Veldhuisen DJ, Crijns HJ, et al. Value of ambulatory electrocardiographic monitoring to identify increased risk of sudden death in patients with left ventricular dysfunction and heart failure. Eur Heart J. 1994;15:928–33.CrossRefPubMed

go back to reference Doval HC, Nul DR, Grancelli HO, et al. Non sustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA- GEMA investigators. Circulation. 1996;94:3198–203.CrossRefPubMed Doval HC, Nul DR, Grancelli HO, et al. Non sustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA- GEMA investigators. Circulation. 1996;94:3198–203.CrossRefPubMed

go back to reference The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.CrossRef The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.CrossRef

go back to reference Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91:2195–203.CrossRefPubMed Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91:2195–203.CrossRefPubMed

go back to reference Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the cardiac arrest study Hamburg). Am Heart J. 1994;127(4 Pt 2):1139–44.CrossRefPubMed Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the cardiac arrest study Hamburg). Am Heart J. 1994;127(4 Pt 2):1139–44.CrossRefPubMed

go back to reference Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.CrossRefPubMed Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.CrossRefPubMed

go back to reference Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the cardiac arrest study Hamburg (CASH). Circulation. 2000;102:748–54.CrossRefPubMed Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the cardiac arrest study Hamburg (CASH). Circulation. 2000;102:748–54.CrossRefPubMed

go back to reference Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study Hamburg. Canadian implantable defibrillator study. Eur Heart J. 2000;21:2071–8.CrossRefPubMed Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study Hamburg. Canadian implantable defibrillator study. Eur Heart J. 2000;21:2071–8.CrossRefPubMed

go back to reference • Bardy GH, Lee KL, Mark DB, et al. Sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. This trial justifies defibrillator therapy benefits in preventing sudden cardiac death. CrossRefPubMed • Bardy GH, Lee KL, Mark DB, et al. Sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. This trial justifies defibrillator therapy benefits in preventing sudden cardiac death. CrossRefPubMed

go back to reference Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170–6.CrossRefPubMedPubMedCentral Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170–6.CrossRefPubMedPubMedCentral

go back to reference Moss AJ, Zareba W, Hall WJ, et al. Multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.CrossRefPubMed Moss AJ, Zareba W, Hall WJ, et al. Multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.CrossRefPubMed

go back to reference • Goldenberg I, Moss AJ, McNitt S, et al. MADIT-II investigators. Time dependence of defibrillator benefit after coronary revascularisation in the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol. 2006;47:1811–7. This trial instructs the guidelines on ICD implantation following myocardial infarction and revascularization therapy. CrossRefPubMed • Goldenberg I, Moss AJ, McNitt S, et al. MADIT-II investigators. Time dependence of defibrillator benefit after coronary revascularisation in the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol. 2006;47:1811–7. This trial instructs the guidelines on ICD implantation following myocardial infarction and revascularization therapy. CrossRefPubMed

go back to reference Kadish A, Dyer A, Daubert JP. Et al; defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–8.CrossRefPubMed Kadish A, Dyer A, Daubert JP. Et al; defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–8.CrossRefPubMed

go back to reference Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874–9.CrossRefPubMed Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874–9.CrossRefPubMed

go back to reference Priori SG, Blomström-Lundqvist C, Mazzanti A, Authors/Task Force Members; Document Reviewers, et al. 2015 ESC guidelines for the Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867.CrossRefPubMed Priori SG, Blomström-Lundqvist C, Mazzanti A, Authors/Task Force Members; Document Reviewers, et al. 2015 ESC guidelines for the Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867.CrossRefPubMed

go back to reference Epstein AE, Kay GN, Plumb VJ, ACT Investigators, et al. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm. 2009;6:1136–43.CrossRefPubMed Epstein AE, Kay GN, Plumb VJ, ACT Investigators, et al. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm. 2009;6:1136–43.CrossRefPubMed

go back to reference Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J. 2007;28:1746–9.CrossRefPubMed Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J. 2007;28:1746–9.CrossRefPubMed

go back to reference Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med. 2010;153:592–9.CrossRefPubMed Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med. 2010;153:592–9.CrossRefPubMed

go back to reference Setoguchi S, Nohria A, Rassen JA, Stevenson LW, Schneeweiss S. maximum Potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure. CMAJ. 2009;180:611–6.CrossRefPubMedPubMedCentral Setoguchi S, Nohria A, Rassen JA, Stevenson LW, Schneeweiss S. maximum Potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure. CMAJ. 2009;180:611–6.CrossRefPubMedPubMedCentral

go back to reference Dewland TA, Pellegrini CN, Wang Y, et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol. 2011;58:1007–13.CrossRefPubMed Dewland TA, Pellegrini CN, Wang Y, et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol. 2011;58:1007–13.CrossRefPubMed

go back to reference Gold MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator post-market approval study: clinical characteristics and perioperative results. Heart Rhythm. 2017; https://doi.org/10.1016/j.hrthm.2017.05.016. Gold MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator post-market approval study: clinical characteristics and perioperative results. Heart Rhythm. 2017; https://​doi.​org/​10.​1016/​j.​hrthm.​2017.​05.​016.

go back to reference Young JB, Abraham WT, Smith AL, Multicenter InSync ICD Randomized Clinical Evaluation MIRACLE ICD) Trial Investigators, et al. Combined cardiac resynchronisation and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. 2003;289:2685–94.CrossRefPubMed Young JB, Abraham WT, Smith AL, Multicenter InSync ICD Randomized Clinical Evaluation MIRACLE ICD) Trial Investigators, et al. Combined cardiac resynchronisation and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. 2003;289:2685–94.CrossRefPubMed

go back to reference Bristow MR, Saxon LA, Boehmer J, et al. Comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.CrossRefPubMed Bristow MR, Saxon LA, Boehmer J, et al. Comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.CrossRefPubMed

go back to reference Cleland JG, Daubert JC, Erdmann E, Cardiac ResynchronizationHeart Failure (CARE-HF) Study Investigators, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRefPubMed Cleland JG, Daubert JC, Erdmann E, Cardiac ResynchronizationHeart Failure (CARE-HF) Study Investigators, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRefPubMed

go back to reference Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation. 2010;122:2022–30.CrossRefPubMedPubMedCentral Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation. 2010;122:2022–30.CrossRefPubMedPubMedCentral

go back to reference Gold MR, Thébault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. Circulation. 2012;126:822–9.CrossRefPubMed Gold MR, Thébault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. Circulation. 2012;126:822–9.CrossRefPubMed

go back to reference Cunnington C, Kwok CS, Satchithananda DK, et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart. 2015;101:1456–62.CrossRefPubMed Cunnington C, Kwok CS, Satchithananda DK, et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart. 2015;101:1456–62.CrossRefPubMed

go back to reference Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J. 2012;163:260–7.e3.CrossRefPubMedPubMedCentral Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J. 2012;163:260–7.e3.CrossRefPubMedPubMedCentral

go back to reference Moss AJ, Hall WJ, Cannom DS, MADIT-CRT Trial Investigators, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.CrossRefPubMed Moss AJ, Hall WJ, Cannom DS, MADIT-CRT Trial Investigators, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.CrossRefPubMed

go back to reference Tang AS, Wells GA, Talajic M, Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.CrossRefPubMed Tang AS, Wells GA, Talajic M, Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.CrossRefPubMed

go back to reference Wilkoff BL, Cook JR, Epstein AE, Dual Chamber and VVI Implantable Defibrillator Trial Investigators, et al. Dual-chamber pacing or ventricular back-up pacing in patients with an implantable defibrillator: the dual chamber and VVI implantable defibrillator (DAVID) trial. JAMA. 2002;288:3115–23.CrossRefPubMed Wilkoff BL, Cook JR, Epstein AE, Dual Chamber and VVI Implantable Defibrillator Trial Investigators, et al. Dual-chamber pacing or ventricular back-up pacing in patients with an implantable defibrillator: the dual chamber and VVI implantable defibrillator (DAVID) trial. JAMA. 2002;288:3115–23.CrossRefPubMed

go back to reference Sweeney MO, Hellkamp AS, Ellenbogen KA, MOde Selection Trial Investigators, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932–7.CrossRefPubMed Sweeney MO, Hellkamp AS, Ellenbogen KA, MOde Selection Trial Investigators, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932–7.CrossRefPubMed

go back to reference Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: the RD-CHF study. Pacing Clin Electrophysiol. 2007;30(Suppl 1):S23–30.PubMed Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: the RD-CHF study. Pacing Clin Electrophysiol. 2007;30(Suppl 1):S23–30.PubMed

go back to reference • Curtis AB, Worley SJ, Adamson PB, Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585–93. This trial is instructive in planning pacing strategy in patients with high pacing requirements. CrossRefPubMed • Curtis AB, Worley SJ, Adamson PB, Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585–93. This trial is instructive in planning pacing strategy in patients with high pacing requirements. CrossRefPubMed

go back to reference Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2011;8:1088–94.CrossRefPubMed Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2011;8:1088–94.CrossRefPubMed

go back to reference Upadhyay GA, Choudhry NK, Auricchio A, Ruskin J, Singh JP. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52:1239–46.CrossRefPubMed Upadhyay GA, Choudhry NK, Auricchio A, Ruskin J, Singh JP. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52:1239–46.CrossRefPubMed

go back to reference Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (cardiac resynchronization therapy in atrial fibrillation patients multinational registry). JACC Heart Fail. 2013;1:500–7.CrossRefPubMed Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (cardiac resynchronization therapy in atrial fibrillation patients multinational registry). JACC Heart Fail. 2013;1:500–7.CrossRefPubMed

go back to reference Penn J, Goldenberg I, Moss AJ, MADIT-CRT Trial Investigators, et al. Improved outcome with preventive cardiac resynchronization therapy in the elderly: a MADIT-CRT substudy. J Cardiovasc Electrophysiol. 2011;22:892–7.CrossRefPubMed Penn J, Goldenberg I, Moss AJ, MADIT-CRT Trial Investigators, et al. Improved outcome with preventive cardiac resynchronization therapy in the elderly: a MADIT-CRT substudy. J Cardiovasc Electrophysiol. 2011;22:892–7.CrossRefPubMed

go back to reference Killu AM, Wu JH, Friedman PA, et al. Outcomes of cardiac resynchronization therapy in the elderly. Pacing Clin Electrophysiol. 2013;36:664–72.CrossRefPubMed Killu AM, Wu JH, Friedman PA, et al. Outcomes of cardiac resynchronization therapy in the elderly. Pacing Clin Electrophysiol. 2013;36:664–72.CrossRefPubMed

go back to reference Höke U, Putter H, Van Der Velde ET, et al. Left ventricular reverse remodeling, device-related adverse events, and long-term outcome after cardiac resynchronization therapy in the elderly. Circ Cardiovasc Qual Outcomes. 2014;7:437–44.CrossRefPubMed Höke U, Putter H, Van Der Velde ET, et al. Left ventricular reverse remodeling, device-related adverse events, and long-term outcome after cardiac resynchronization therapy in the elderly. Circ Cardiovasc Qual Outcomes. 2014;7:437–44.CrossRefPubMed

go back to reference Olechowski B, Sands R, Zachariah D, et al. Is cardiac resynchronisation therapy feasible, safe and beneficial in the very elderly? J Geriatr Cardiol. 2015;12:497–501.PubMedPubMedCentral Olechowski B, Sands R, Zachariah D, et al. Is cardiac resynchronisation therapy feasible, safe and beneficial in the very elderly? J Geriatr Cardiol. 2015;12:497–501.PubMedPubMedCentral

go back to reference Dickstein K, Vardas PE, Auricchio A, Committee for Practice Guidelines of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG), et al. 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the heart failure association and the European heart rhythm association. Eur J Heart Fail. 2010;12:1143–53.CrossRefPubMed Dickstein K, Vardas PE, Auricchio A, Committee for Practice Guidelines of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG), et al. 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the heart failure association and the European heart rhythm association. Eur J Heart Fail. 2010;12:1143–53.CrossRefPubMed

go back to reference Yancy CW, Jessup M, Bozkurt B, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.CrossRefPubMed

go back to reference Thibault B, Harel F, Ducharme A, LESSER-EARTH Investigators, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex. Circulation. 2013 26;127(8):873-81. https://doi.org/10.1161/CIRCULATIONAHA.112.001239 Thibault B, Harel F, Ducharme A, LESSER-EARTH Investigators, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex. Circulation. 2013 26;127(8):873-81. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​112.​001239

go back to reference Thibault B, Harel F, Ducharme A, LESSER-EARTH Investigators, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the evaluation of resynchronization therapy for heart failure (LESSER-EARTH) trial. Circulation. 2013;127:873–81.CrossRefPubMed Thibault B, Harel F, Ducharme A, LESSER-EARTH Investigators, et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the evaluation of resynchronization therapy for heart failure (LESSER-EARTH) trial. Circulation. 2013;127:873–81.CrossRefPubMed

go back to reference Ruschitzka F, Abraham WT, Singh JP, EchoCRT Study Group, et al. Cardiac- resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–405.CrossRefPubMed Ruschitzka F, Abraham WT, Singh JP, EchoCRT Study Group, et al. Cardiac- resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–405.CrossRefPubMed

go back to reference Versteeg H, Schiffer AA, Widdershoven JW, et al. Response to cardiac resynchronization therapy: is it time to expand the criteria? Pacing Clin Electrophysiol. 2009;32:1247–56.CrossRefPubMed Versteeg H, Schiffer AA, Widdershoven JW, et al. Response to cardiac resynchronization therapy: is it time to expand the criteria? Pacing Clin Electrophysiol. 2009;32:1247–56.CrossRefPubMed

go back to reference Packer M. Proposal for a new clinical end point to evaluate the ef cacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7:176–82.CrossRefPubMed Packer M. Proposal for a new clinical end point to evaluate the ef cacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7:176–82.CrossRefPubMed

go back to reference Pitzalis MV, Iacoviello M, Romito R, et al. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol. 2002;40:1615–22.CrossRefPubMed Pitzalis MV, Iacoviello M, Romito R, et al. Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony. J Am Coll Cardiol. 2002;40:1615–22.CrossRefPubMed

go back to reference Bleeker GB, Bax JJ, Fung JW, et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol. 2006;97:260–3.CrossRefPubMed Bleeker GB, Bax JJ, Fung JW, et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol. 2006;97:260–3.CrossRefPubMed

go back to reference Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J. 2007;153:105–12.CrossRefPubMed Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J. 2007;153:105–12.CrossRefPubMed

go back to reference Chalil S, Foley PW, Muyhaldeen SA, et al. Late gadolinium enhancement- cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace. 2007;9:1031–7.CrossRefPubMed Chalil S, Foley PW, Muyhaldeen SA, et al. Late gadolinium enhancement- cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace. 2007;9:1031–7.CrossRefPubMed

go back to reference Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall brosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2012;60:1659–67.CrossRefPubMed Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall brosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2012;60:1659–67.CrossRefPubMed

go back to reference Chalil S, Stegemann B, Muhyaldeen S, et al. Intraventricular dyssynchrony predicts mortality and morbidity following cardiac resynchronization therapy: a study using cardiovascular magnetic resonance tissue synchronization imaging. J Am Coll Cardiol. 2007;50:243–52.CrossRefPubMed Chalil S, Stegemann B, Muhyaldeen S, et al. Intraventricular dyssynchrony predicts mortality and morbidity following cardiac resynchronization therapy: a study using cardiovascular magnetic resonance tissue synchronization imaging. J Am Coll Cardiol. 2007;50:243–52.CrossRefPubMed

go back to reference Arshad A, Moss AJ, Foster E, MADIT-CRT Executive Committee, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (multicenter automatic de brillator implantation trial with cardiac resynchronization therapy) trial. J Am Coll Cardiol. 2011;57:813–20.CrossRefPubMed Arshad A, Moss AJ, Foster E, MADIT-CRT Executive Committee, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (multicenter automatic de brillator implantation trial with cardiac resynchronization therapy) trial. J Am Coll Cardiol. 2011;57:813–20.CrossRefPubMed

go back to reference Leyva F, Foley PW, Chalil S, Irwin N, Smith RE. Female gender is associated with a better outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2011;34:82–8.CrossRefPubMed Leyva F, Foley PW, Chalil S, Irwin N, Smith RE. Female gender is associated with a better outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2011;34:82–8.CrossRefPubMed

go back to reference Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608–16.CrossRefPubMed Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608–16.CrossRefPubMed

go back to reference Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol. 2012;59:1509–18.CrossRefPubMed Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol. 2012;59:1509–18.CrossRefPubMed

go back to reference Saba S, Marek J, Schwartzman D, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the speckle tracking assisted resynchronization therapy for electrode region trial. Circ Heart Fail. 2013;6:427–34.CrossRefPubMed Saba S, Marek J, Schwartzman D, et al. Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy: results of the speckle tracking assisted resynchronization therapy for electrode region trial. Circ Heart Fail. 2013;6:427–34.CrossRefPubMed

go back to reference Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:29–38.CrossRefPubMedPubMedCentral Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:29–38.CrossRefPubMedPubMedCentral

go back to reference Pappone C, Ćalović Ž, Vicedomini G, Cuko A, et al. Improving cardiac resynchronization therapy response with multipoint left ventricular pacing: twelve-month follow-up study. Heart Rhythm. 2015;12(6):1250–8. https://doi.org/10.1016/j.hrthm.2015.02.008.CrossRefPubMed Pappone C, Ćalović Ž, Vicedomini G, Cuko A, et al. Improving cardiac resynchronization therapy response with multipoint left ventricular pacing: twelve-month follow-up study. Heart Rhythm. 2015;12(6):1250–8. https://​doi.​org/​10.​1016/​j.​hrthm.​2015.​02.​008.CrossRefPubMed

go back to reference White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol. 2006;48:1953–60.CrossRefPubMed White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol. 2006;48:1953–60.CrossRefPubMed

go back to reference Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography- guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010;122:2660–8.CrossRefPubMed Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography- guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010;122:2660–8.CrossRefPubMed

go back to reference Abraham WT, Gras D, Yu CM, Guzzo L, Gupta MS, FREEDOM Steering Committee. Rationale and design of a randomized clinical trial to assess the safety and ef cacy of frequent optimization of cardiac resynchronization therapy: the frequent optimization study using the QuickOpt method (FREEDOM) trial. Am Heart J. 2010;159:944–948.e1.CrossRefPubMed Abraham WT, Gras D, Yu CM, Guzzo L, Gupta MS, FREEDOM Steering Committee. Rationale and design of a randomized clinical trial to assess the safety and ef cacy of frequent optimization of cardiac resynchronization therapy: the frequent optimization study using the QuickOpt method (FREEDOM) trial. Am Heart J. 2010;159:944–948.e1.CrossRefPubMed

go back to reference Martin DO, Lemke B, Birnie D, Adaptive CRT Study Investigators, et al. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm. 2012;9:1807–14.CrossRefPubMed Martin DO, Lemke B, Birnie D, Adaptive CRT Study Investigators, et al. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm. 2012;9:1807–14.CrossRefPubMed

go back to reference Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002;13:399–405.CrossRefPubMed Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002;13:399–405.CrossRefPubMed

go back to reference Carson PE, Johnson GR, Dunkman WB, for the V-HeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT studies. Circulation. 1993;87:VI-102–10. Carson PE, Johnson GR, Dunkman WB, for the V-HeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT studies. Circulation. 1993;87:VI-102–10.

go back to reference Deedwania PC, Singh BN, Ellenbogen KA, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observation from the veterans affairs congestive heart failure trial on antiarrhythmic therapy (CHF-STAT). Circulation. 1998;98:2574–9.CrossRefPubMed Deedwania PC, Singh BN, Ellenbogen KA, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observation from the veterans affairs congestive heart failure trial on antiarrhythmic therapy (CHF-STAT). Circulation. 1998;98:2574–9.CrossRefPubMed

go back to reference Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation. 1991;84:40–8.CrossRefPubMed Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation. 1991;84:40–8.CrossRefPubMed

go back to reference The CONSENSUS. Trial study group: effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian Enalapril survival study (CONSENSUS). N Engl J Med. 1987;316:1429–35.CrossRef The CONSENSUS. Trial study group: effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian Enalapril survival study (CONSENSUS). N Engl J Med. 1987;316:1429–35.CrossRef

go back to reference Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med. 2007;357:1000–8.CrossRefPubMed Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med. 2007;357:1000–8.CrossRefPubMed

go back to reference Brenyo A, Link MS, Barsheshet A, et al. Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT. J Am Coll Cardiol. 2011;58:1682–9.CrossRefPubMed Brenyo A, Link MS, Barsheshet A, et al. Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT. J Am Coll Cardiol. 2011;58:1682–9.CrossRefPubMed

go back to reference Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol. 2006;48:734–43.CrossRefPubMed Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol. 2006;48:734–43.CrossRefPubMed

go back to reference Sharma PS, Dandamudi G, Naperkowski A, Oren JW, Storm RH, Ellenbogen KA, et al. Permanent his-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice. Heart Rhythm. 2015;12(2):305–12.CrossRefPubMed Sharma PS, Dandamudi G, Naperkowski A, Oren JW, Storm RH, Ellenbogen KA, et al. Permanent his-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice. Heart Rhythm. 2015;12(2):305–12.CrossRefPubMed

go back to reference Dresing TJ, Natale A. Congestive heart failure treatment: the pacing approach. Heart Fail Rev. 2001;6(1):15–25.CrossRefPubMed Dresing TJ, Natale A. Congestive heart failure treatment: the pacing approach. Heart Fail Rev. 2001;6(1):15–25.CrossRefPubMed

go back to reference Tanno K, Miyoshi F, Watanabe N, MADIT II. The Multicenter Automtic De brillator Implantation Trial, et al. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J. 2005;69:19–22.CrossRefPubMed Tanno K, Miyoshi F, Watanabe N, MADIT II. The Multicenter Automtic De brillator Implantation Trial, et al. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J. 2005;69:19–22.CrossRefPubMed

go back to reference Cannom DS, Rider AK, Stinson EB, Harrison DC. Electrophysiologic studies in the denervated transplanted human heart. II. Response to norepinephrine, isoproterenol and propranolol. Am J Cardiol. 1975;36:859.CrossRefPubMed Cannom DS, Rider AK, Stinson EB, Harrison DC. Electrophysiologic studies in the denervated transplanted human heart. II. Response to norepinephrine, isoproterenol and propranolol. Am J Cardiol. 1975;36:859.CrossRefPubMed

go back to reference Yusuf S, Theodoropoulos S, Mathias CJ, et al. Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta-adrenergic blockade. Circulation. 1987;75:696.CrossRefPubMed Yusuf S, Theodoropoulos S, Mathias CJ, et al. Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta-adrenergic blockade. Circulation. 1987;75:696.CrossRefPubMed

go back to reference Ellenbogen KA, Thames MD, DiMarco JP, et al. Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. Circulation. 1990;81:821.CrossRefPubMed Ellenbogen KA, Thames MD, DiMarco JP, et al. Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. Circulation. 1990;81:821.CrossRefPubMed

go back to reference Enriquez AD, Calenda B, Miller MA, Anyanwu AC, Pinney SP. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol. 2013;6(4):668–74. https://doi.org/10.1161/CIRCEP.113.000457.CrossRefPubMed Enriquez AD, Calenda B, Miller MA, Anyanwu AC, Pinney SP. The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol. 2013;6(4):668–74. https://​doi.​org/​10.​1161/​CIRCEP.​113.​000457.CrossRefPubMed

go back to reference Zipes DP, et al. Determining the feasibility of spinal cord Neuromodulation for the treatment of chronic systolic heart failure: the DEFEAT-HF study. JACC Heart Fail. 2016;4:129–36.CrossRefPubMed Zipes DP, et al. Determining the feasibility of spinal cord Neuromodulation for the treatment of chronic systolic heart failure: the DEFEAT-HF study. JACC Heart Fail. 2016;4:129–36.CrossRefPubMed

go back to reference Halbach M, Fritz T, et al. Baroreflex activation therapy in heart failure with reduced ejection fraction: available data and future perspective. Curr Heart Fail Rep. 2016;13(2):71–6.CrossRefPubMed Halbach M, Fritz T, et al. Baroreflex activation therapy in heart failure with reduced ejection fraction: available data and future perspective. Curr Heart Fail Rep. 2016;13(2):71–6.CrossRefPubMed

go back to reference Dorian P, Philippon F, Thibault B, et al. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm. 2004;1:540–7.CrossRefPubMed Dorian P, Philippon F, Thibault B, et al. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm. 2004;1:540–7.CrossRefPubMed

go back to reference Bänsch D, Steffgen F, Grönefeld G, et al. The 1+1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation. 2004;110:1022–9.CrossRefPubMed Bänsch D, Steffgen F, Grönefeld G, et al. The 1+1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation. 2004;110:1022–9.CrossRefPubMed

go back to reference Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation. 2006;113:2871–9.CrossRefPubMed Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation. 2006;113:2871–9.CrossRefPubMed

go back to reference Swerdlow CD, Chen PS, Kass RM, Allard JR, Peter CT. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. JAm Coll Cardiol. 1994;23:1342–55.CrossRef Swerdlow CD, Chen PS, Kass RM, Allard JR, Peter CT. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. JAm Coll Cardiol. 1994;23:1342–55.CrossRef

go back to reference Rinaldi CA, Simon RD, Baszko A, et al. A 17 year experience of inappropriate shock therapy in patients with implantable cardioverterdefibrillators: are we getting any better? Heart. 2004;90:330–1.CrossRefPubMedPubMedCentral Rinaldi CA, Simon RD, Baszko A, et al. A 17 year experience of inappropriate shock therapy in patients with implantable cardioverterdefibrillators: are we getting any better? Heart. 2004;90:330–1.CrossRefPubMedPubMedCentral

go back to reference •• Epstein AE, DiMarco JP, Ellenbogen KA, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and Antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1–62. The Guidelines for device implantation are comprehensive and updated regularly. CrossRefPubMed •• Epstein AE, DiMarco JP, Ellenbogen KA, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and Antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1–62. The Guidelines for device implantation are comprehensive and updated regularly. CrossRefPubMed

go back to reference Yu CM, Fung WH, Lin H, et al. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol. 2003;91:684–8.CrossRefPubMed Yu CM, Fung WH, Lin H, et al. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol. 2003;91:684–8.CrossRefPubMed

go back to reference Lee E, Chen R, Aziz S, et al. Socio cultural barriers to device therapy among Asian patients with heart failure. Eur J Heart Fail. 2012;11(Suppl 1):S268. Lee E, Chen R, Aziz S, et al. Socio cultural barriers to device therapy among Asian patients with heart failure. Eur J Heart Fail. 2012;11(Suppl 1):S268.

go back to reference Knight CS, Tallaj JA, Rayburn BK, et al. Bradycardia and syncope as a presentation of cardiac allograft rejection involving the conducting system. Cardiovasc Pathol. 2010;19:117.CrossRefPubMed Knight CS, Tallaj JA, Rayburn BK, et al. Bradycardia and syncope as a presentation of cardiac allograft rejection involving the conducting system. Cardiovasc Pathol. 2010;19:117.CrossRefPubMed

go back to reference Tse HF, Turner S, Sanders P, et al. The Dual Targeted Thoracic Spinal Cord Stimulation for HEArt Failure as a Restorative Treatment: First-In-Man Experience. Heart Rhythm 2015;12(3). Tse HF, Turner S, Sanders P, et al. The Dual Targeted Thoracic Spinal Cord Stimulation for HEArt Failure as a Restorative Treatment: First-In-Man Experience. Heart Rhythm 2015;12(3).